Consumer Medicine Information (CMI) summary
The
full CMI on the next page has more details. If you are worried about using this medicine,
speak to your doctor or pharmacist.
1. Why am I receiving MENVEO?
MENVEO is a vaccine used for the active immunisation of children (from the age of
2 months), adolescents and adults to prevent invasive disease caused by Neisseria
meningitidis serogroups A, C, W-135 and Y. Neisseria meningitidis can cause meningitis,
a very serious disease.
2. What should I know before I receive MENVEO?
Do not use if you have ever had an allergic reaction to MENVEO, diphtheria toxoid
(used in other vaccines) or any of the ingredients listed at the end of the CMI.
Talk to your doctor if you have any other medical conditions, take any other medicines,
or are pregnant or plan to become pregnant or are breastfeeding.
3. What if I am taking other medicines?
Some medicines may interfere with MENVEO and affect how it works.
4. How do I receive MENVEO?
Your doctor or nurse will give you MENVEO as an injection into your upper arm or upper
thigh muscle (for children under 2 years of age).
5. What should I know after receiving MENVEO?
Things you should do
|
Keep a record of your immunisation history.
|
Driving or using machines
|
Be careful before you drive or use any machines or tools until you know how MENVEO
affects you.
|
Looking after your medicine
|
MENVEO will normally be stored at the doctor’s surgery or in the pharmacy.
If you need to store MENVEO, keep it in the refrigerator between 2oC and 8oC. Do not freeze.
|
6. Are there any side effects?
Side effects which have been reported following administration of MENVEO include redness,
firmness and/or pain at the injection site, injection site itching, inflammation including
swelling of the injected limb, enlarged lymph nodes near the injection site, tiredness,
sore throat, rash, headaches, muscle aches, joint aches, fever, chills, a general
feeling of being unwell, nausea, impaired hearing, ear pain, spinning sensation.
Allergic reactions have also occurred following administration of MENVEO. Allergy
is rare and severe reactions will usually occur within the first few hours of vaccination.
If this occurs go to the Emergency Department of the nearest hospital immediately.
Active ingredient(s):
meningococcal (groups A, C, W-135 and Y) oligosaccharide CRM
197
conjugate vaccine
Consumer Medicine Information (CMI)
This leaflet provides important information about MENVEO. You should also speak to your doctor or nurse if you would like further information
or if you have any concerns or questions about receiving MENVEO.
Where to find information in this leaflet:
1. Why am I receiving MENVEO?
MENVEO is a vaccine used for active immunisation of children (from the age of 2 months),
adolescents and adults to prevent invasive disease caused by Neisseria meningitidis
serogroups A, C, W-135 and Y.
Meningitis is an infection of the spinal fluid and the tissues that surround the brain.
Of the microbes that cause meningitis, one of the most severe is Neisseria meningitidis
(meningococcus). Meningococcal meningitis is an infectious disease that is spread
from person to person. It is a very serious disease and is sometimes fatal. It can
cause permanent physical and neurological damage.
MENVEO can only protect you or your child from meningitis caused by four groups of
Neisseria meningitidis (A, C, W-135 and Y). It will not protect you or your child
from meningitis caused by other groups of Neisseria meningitidis or from meningitis
caused by different kinds of microbes.
MENVEO works by causing your body to produce its own protection (antibodies) against
meningococcal bacteria. Your body usually takes a couple of weeks after vaccination
to develop protection against Neisseria meningitidis.
If a vaccinated person comes into contact with Neisseria meningitidis, the body is
usually able to destroy it. However, as with all vaccines, 100% protection cannot
be guaranteed.
Sometimes individuals may react unfavourably to the vaccine. The chance of a severe
reaction from MENVEO is very small but the risks from not being vaccinated against
meningococcal disease may be very serious.
2. What should I know before I receive MENVEO?
Warnings
Do not receive MENVEO if:
you are allergic to MENVEO or any of the ingredients listed at the end of this leaflet
Always check the ingredients to make sure you can use this medicine.
you have ever had an allergic reaction to diphtheria toxoid (a substance used in other
vaccines)
you have a very high fever
In this case your vaccination with MENVEO may have to be delayed. Discuss this with
your doctor or nurse before you receive MENVEO.
you have had an allergic reaction or become unwell after receiving another meningococcal
vaccine
you have a severe infection with a high temperature
A minor infection such as a cold should not be a problem however talk to your doctor
or nurse about this before being vaccinated.
Check with your doctor if you:
have any other medical conditions including any that involve your immune system
have a low blood platelet count
receive treatment that blocks the part of the immune system known as complement activation,
such as eculizumab
Even if you have been vaccinated with MENVEO you can remain at increased risk of disease
caused by Neisseria meningitidis groups A, C, W-135 and Y.
take any medicines for any other condition
have an allergy to latex
have had an allergic reaction after any other vaccination. Symptoms include difficulty
breathing, swelling of the throat, fits (convulsions) including fits associated with
fevers, high fevers and severe reactions at the injection site.
You may be at risk of developing certain side effects. It is important you understand
these risks and how to monitor for them. See additional information under Section
6. Are there any side effects?
Pregnancy and breastfeeding
Check with your doctor if you are pregnant or intend to become pregnant.
Talk to your doctor if you are breastfeeding or intend to breastfeed.
They will discuss with you the benefits and risks of receiving MENVEO during pregnancy
or whilst breastfeeding.
Fainting
Fainting can occur following, or even before, any needle injection. Tell the person
giving you your injection if you or your child have ever fainted with a previous injection.
3. What if I am taking other medicines?
Tell your doctor or nurse if you are taking any other medicines, including any medicines,
vitamins or supplements that you buy without a prescription from your pharmacy, supermarket
or health food shop.
Some medicines may interfere with MENVEO and affect how it works.
Tell your doctor or nurse if you or your child have had any vaccines recently.
MENVEO may be given at the same time as other vaccinations.
Other vaccines must be injected into a different arm or leg (for children aged 2-23
months) from the site of the MENVEO injection. These include:
tetanus, reduced diphtheria and acellular pertussis vaccine
human papillomavirus vaccine
Check with your doctor or nurse if you are not sure about what medicines, vitamins
or supplements you are taking and if these affect MENVEO.
4. How do I receive MENVEO?
How much is given
Your doctor or nurse will give you MENVEO as an injection
The dose is 0.5 mL
How is it given
MENVEO is injected into your upper arm or for children under 2 years of age into the
thigh muscle
It should not be injected directly into a blood vessel
If you are given too much MENVEO
If you think that you have been given too much MENVEO, you may need urgent medical
attention.
You should immediately:
phone the Poisons Information Centre
(by calling
13 11 26), or
contact your doctor, or
go to the Emergency Department at your nearest hospital.
You should do this even if there are no signs of discomfort or poisoning.
5. What should I know after receiving MENVEO?
Things you should do
keep a record of your vaccination history
Driving or using machines
Be careful before you drive or use any machines or tools until you know how MENVEO
affects you.
Looking after your medicine
MENVEO will usually be stored at the doctor’s clinic or at the pharmacy.
If you need to store MENVEO it is important to keep it in the refrigerator between
2oC and 8oC in the original pack.
Do not freeze MENVEO.
Following reconstitution and in order to reduce microbiological hazard, MENVEO should
be used as soon as practicable after reconstitution. If storage is necessary, keep
MENVEO in the refrigerator between 2oC and 8oC for no more than 24 hours.
Keep it where young children cannot reach it.
Getting rid of any unwanted medicine
Do not use this medicine after the expiry date.
The vials let over after administration of MENVEO must be disposed of as medical waste.
6. Are there any side effects?
All medicines can have side effects. If you do experience any side effects, most of
them are minor and temporary. However, some side effects may need medical attention.
See the information below and, if you need to, ask your doctor or nurse if you have
any further questions about side effects.
Your doctor or nurse might ask you to remain for observation following vaccination.
Less serious side effects
Serious side effects
Tell your doctor or nurse if you notice anything else that may be making you feel
unwell.
Other side effects not listed here may occur in some people.
Reporting side effects
After you have received medical advice for any side effects you experience, you can
report side effects to the Therapeutic Goods Administration online at
www.tga.gov.au/reporting-problems . By reporting side effects, you can help provide more information on the safety of
this medicine.
Always make sure you speak to your doctor or nurse before you decide to stop taking
any of your medicines.
7. Product details
This medicine is only available with a doctor's prescription.
What MENVEO contains
Active ingredient
(main ingredient)
|
MenA vial:
Meningococcal oligosaccharide group A
Men CWY vial:
Meningococcal oligosaccharide group C
Meningococcal oligosaccharide group W135
Meningococcal oligosaccharide group Y
|
Other ingredients
(inactive ingredients)
|
MenA vial:
monobasic potassium phosphate
sucrose
MenCWY vial:
dibasic sodium phosphate dihydrate
monobasic sodium phosphate monohydrate
sodium chloride
water for injections
|
MENVEO does not contain lactose, gluten, thiomersal (organic mercurial), tartrazine
or any other azo dyes.
Do not take this medicine if you are allergic to any of these ingredients.
What MENVO looks like
Each dose of MENVEO is made up of 2 vials:
Vial containing the MenA lyophilised conjugate component as a white to off-white powder
Vial containing the MenCWY liquid conjugate component as a clear solution
The contents of both vials (MenA vial and MenCWY vial) are mixed prior to vaccination.
MENVEO is available as either a single dose (2 vials) pack or a 5 dose (10 vials)
multipack (AUST R 192696).
Not all presentations and pack sizes may be marketed.
Who distributes MENVEO
GlaxoSmithKline Australia Pty Ltd
Level 4, 436 Johnston Street
Abbotsford, VIC 3067
Trade marks are owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
This leaflet was prepared on 10 November 2022.
Version 7.0